Description
ADCC-Enhanced anti-RAGE (11E6) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Inflammatory Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced RAGE antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
AGER
Full Name
advanced glycosylation end product-specific receptor
Background
The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimers disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847).
Alternative Names
AGER; advanced glycosylation end product-specific receptor; RAGE; RAGE isoform sRAGE-delta; RAGE isoform NtRAGE-delta; receptor for advanced glycation end-products variant 20
Gene ID
177
Cellular Localization
Nucleus
Involvement in Disease
Diseases associated with AGER include Diabetic Angiopathy and Leukostasis.
Related Pathways
Its related pathways are amb2 Integrin signaling and Activated TLR4 signalling.
Function
Mediates the interaction of advanced glycation end products (AGE). These non-enzymatic glycosylated proteins accumulate in blood vessel tissues during aging, and accumulate at an accelerated rate in diabetes. As a mediator of acute and chronic vascular inflammation, such as atherosclerosis, especially a complication of diabetes. Age/anger signals play an important role in regulating the production/expression of tnf -, oxidative stress and endothelial dysfunction in type 2 diabetes. The interaction with S100A12 on endothelial cells, monocytes, and lymphocytes triggers cell activation and produces key pro-inflammatory mediators. The interaction with S100B after myocardial infarction may participate in cardiomyocyte apoptosis by activating ERK1/2 and p53/TP53 signaling pathways (similarities). Amyloid peptide receptor. In cortical neurons, amyloid-peptide (ABPP) is transferred from the outside of the cell to the inside of the cell through the cell membrane. The anger signal initiated by ABPP, especially the stimulation of p38 mitogen-activated protein kinase (MAPK), has the ability to drive a transport system that transmits ABPP as an anger complex to the inner space of the nerve. Can also bind oligonucleotides.
Post-translational modifications
1.Glycosylation at Asn25 and Asn81 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
11E6
Description
The antibodys have the ability to inhibit the binding of RAGE to its various ligands. The antibody or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.
Antibody Indication
Inflammatory Diseases
